People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Melinta Therapeutics, Inc. /New/ | — | Pharmaceuticals | Series D+ | $346.8M | $4.9B | 2009 |
| BioAge Labs, Inc. | — | Biotechnology | Series D+ | $194.4M | $2.4B | 2024 |
| Coya Therapeutics, Inc. | — | Biotechnology | Series B | $56.9M | $62.3M | 2022 |
| NeuBase Therapeutics, Inc. | — | Biotechnology | Series A | $17.1M | $42.7M | 2023 |
| Biorelix Inc | — | Pharmaceuticals | Series A | $15.9M | $79.2M | 2009 |
| Geom Therapeutics, Inc. | — | Biotechnology | Series A | $4.4M | $157.4M | 2017 |
Dov Goldstein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dov Goldstein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Johnson | 1 | 25 |
| Garheng Kong | 1 | 16 |
| Patrick Enright | 1 | 10 |
| Vijay Pande | 1 | 9 |
| Campbell Murray | 1 | 9 |
| James Healy | 1 | 8 |
| David Gill | 1 | 8 |
| Richard Kent | 1 | 5 |
| David Snyder | 1 | 5 |
| Dietrich Stephan | 1 | 4 |
| Dieter Weinand | 1 | 4 |
| John H Johnson | 1 | 4 |
| John L. Johnson | 1 | 3 |
| Ira Greenstein | 1 | 3 |
| I Wistar Morris | 1 | 3 |
| P. Sherill Neff | 1 | 3 |
| Jonathan M. Lourie | 1 | 3 |
| Dirk Thye | 1 | 3 |
| Shawn M Titcomb | 1 | 3 |
| Jason Coloma | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.